India Pharma Stocks Bleed Amid Rising FDA Violations
This article was originally published in PharmAsia News
Indian health care shares, once top investor picks, are down sharply from 52-week highs as notices from the US FDA take their toll. Lupin and Natco are the most recent companies to be rapped by the US regulator over lapses in manufacturing standards.
Register for our free email digests: